Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Commercializing Lamprogen's Fluorescent Particles

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced after the close of the market on Thursday a commercialization deal with Lamprogen.

Lamprogen, a University of Washington spinout, has granted Bio-Rad exclusive rights to commercialize a class of bright, stable, and non-toxic fluorescent particles. The particles can be used in a broad array of assays and research applications including flow cytometry, Bio-Rad said, adding it expects to commercialize the products in 2013.

The deal also grants Bio-Rad access to future technologies developed by Lamprogen.

Financial and other terms were not disclosed.

"Combining Lamprogen's unique fluorescent particles with antibodies or other biomolecules will enable our customers to create single and multiplex assays with greater detection capabilities," Brad Crutchfield, Bio-Rad executive vice president and president of the Life Science Group, said in a statement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.